A "joint" statement on inhibitor-bypassing therapy

被引：2

作者：

Hoots, W. Keith ^{[1
]}

机构：

[1] Univ Texas, Austin, TX USA

来源：

BLOOD | 2007年 / 109卷 / 02期

关键词：

D O I：

10.1182/blood-2006-10-053439

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Astermark and colleagues report in this issue of Blood on the first prospective, crossover comparison of the 2 bypassing therapies available for treating hemarthroses in subjects with high-responding factor VIII or IX antibodies: recombinant factor VIIa (rFVIIa) and FEIBA, an activated prothrombin complex concentrate (aPCC).

引用

页码：395 / 396

页数：2

共 4 条

[1]

Key NS, 1998, THROMB HAEMOSTASIS, V80, P912

[2] Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI [J].